Succinic semialdehyde dehydrogenase deficiency

Rare autosomal recessive metabolic disorder

Succinic semialdehyde dehydrogenase deficiency
4-Hydroxybutansäure - 4-Hydroxybutanoic acid.svg
Chemical structure of gamma-Hydroxybutyric acid, elevated in SSADHD
Synonyms	4-hydroxybutyric aciduria, Gamma-hydroxybutyric aciduria, SSADH deficiency
Specialty	Neurology, Medical genetics, Metabolic medicine
Symptoms	Developmental delay, hypotonia, seizures, ataxia, behavioral disturbances, intellectual disability
Complications	Neurological impairment, epilepsy, speech and motor deficits
Usual onset	Infancy or early childhood
Duration	Lifelong
Causes	Genetic mutation affecting the ALDH5A1 gene
Risk factors	Family history (autosomal recessive inheritance)
Diagnosis	Genetic testing, urine organic acid analysis, enzymatic assay
Differential diagnosis	GABA-transaminase deficiency, organic acidurias, other inborn errors of metabolism
Prevention	Genetic counseling
Treatment	Supportive management, physical therapy, seizure management
Medication	Anticonvulsants, pharmacological therapies targeting GABA metabolism
Prognosis	Variable; typically lifelong neurological impairment
Frequency	Extremely rare; approximately 450 documented cases worldwide
Deaths	Rare, mostly due to complications from seizures or associated neurological disorders

File:Autorecessive.svg

Succinic semialdehyde dehydrogenase deficiency has an autosomal recessive pattern of inheritance.

Succinic semialdehyde dehydrogenase deficiency (SSADHD), also known as 4-hydroxybutyric aciduria or Gamma-hydroxybutyric aciduria, is a rare inherited autosomal recessive metabolic disorder characterized by a deficiency of the enzyme succinic semialdehyde dehydrogenase (SSADH). SSADHD deficiency results in the accumulation of gamma-hydroxybutyric acid (GHB) and related substances within the central nervous system, causing various neurological symptoms.

Signs and symptoms

Symptoms of SSADH deficiency typically manifest early in infancy or childhood and may include:

• Developmental delay and intellectual disability
• Hypotonia (low muscle tone)
• Ataxia (impaired coordination and balance)
• Seizures and epilepsy
• Behavioral disturbances (hyperactivity, anxiety, aggression)
• Sleep disturbances
• Speech delays or communication deficits
• Movement disorders (e.g., dystonia, tremors)

Severity varies widely among affected individuals.

Causes

SSADH deficiency is caused by mutations in the ALDH5A1 gene located on chromosome 6p22. This gene encodes the enzyme succinic semialdehyde dehydrogenase, crucial for the metabolism of the neurotransmitter gamma-aminobutyric acid (GABA).

A deficiency in this enzyme leads to increased GABA and gamma-hydroxybutyric acid (GHB) levels in the brain, disrupting normal neurological function and development.

Pathophysiology

Normally, GABA is metabolized into succinic acid by two enzymatic reactions:

1. GABA is converted into succinic semialdehyde by GABA-transaminase.
2. Succinic semialdehyde is then oxidized to succinic acid by SSADH.

When SSADH is deficient, succinic semialdehyde accumulates and is converted instead to gamma-hydroxybutyric acid (GHB), a compound known to disrupt neuronal signaling, contributing to the neurological symptoms characteristic of this disorder.

Diagnosis

Diagnosis typically involves biochemical testing combined with genetic confirmation:

• Urinary organic acid analysis:
  • Demonstrates elevated gamma-hydroxybutyric acid (4-hydroxybutyric acid).
• Genetic testing:
  • Identifies mutations in the ALDH5A1 gene, confirming the diagnosis.
• Enzyme activity assay:
  • Reduced or absent SSADH enzyme activity in fibroblasts or lymphocytes.

Differential diagnosis

Conditions that may present similarly and should be ruled out include:

• GABA-transaminase deficiency
• Organic acidurias (e.g., glutaric aciduria, methylmalonic aciduria)
• Mitochondrial disorders
• Other inborn errors of metabolism presenting with neurological symptoms

Treatment

Currently, no cure for SSADHD deficiency exists. Treatment is supportive and symptomatic, aimed at improving quality of life:

• Antiepileptic drugs for seizure management.
• Physical therapy and occupational therapy for motor deficits and hypotonia.
• Speech therapy to improve communication abilities.
• Behavioral management and supportive educational programs.
• Pharmacological research is ongoing, with potential future therapies targeting GABA metabolism and neurotransmission.

Prognosis

The prognosis is highly variable. Most patients experience lifelong neurological impairment. Intellectual disability and seizures may significantly impact daily life, though supportive care can markedly improve functional outcomes.

Epidemiology

SSADHD deficiency is extremely rare, with approximately 450 documented cases worldwide. The true prevalence may be underestimated due to diagnostic challenges.

Genetic counseling

As an autosomal recessive condition, there is a 25% chance with each pregnancy that two carrier parents will have an affected child. Genetic counseling is recommended for families with a history of SSADHD deficiency to understand inheritance patterns, recurrence risks, and family planning options.

Research directions

Research continues to explore therapies aimed at reducing GHB levels or enhancing SSADH enzyme activity. Clinical trials evaluating novel treatments such as vigabatrin (an irreversible inhibitor of GABA-transaminase) and compounds targeting GABA receptors are ongoing.

See also

• GABA
• Inborn error of metabolism
• Neurometabolic disorder
• GHB

External links

• SSADH deficiency - Genetic and Rare Diseases Information Center (GARD)
• SSADH Association